Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Zawartość zarchiwizowana w dniu 2024-06-18

Embryonic Stem cell-based Novel Alternative Testing Strategies

Cel

"ESNATS aims at developing a novel toxicity test platform based on embryonic stem cells (ESC), especially human ESC (hESC), to accelerate drug development, reduce R&D costs and propose a powerful alternative to animal tests (3 Rs). ESNATS will address current drug-testing shortcomings: - testing takes place late in the development cycle - animal test systems bear the risk of non-prediction due to inter-species variation - non-ESC assays rely on primary cells or cells of malignant origin that are hard-to-standardise and limited in regard to quantity, homogeneity and genetic diversity - existing assay systems based on primary animal cell lines do not reliably represent the physiological situation ESNATS will develop a battery of toxicity tests using hESC lines subjected to different standardised culture protocols. Tests will cover embryoid bodies in different developmental stages and differentiated derivatives including gamete and neuronal lineages, complemented with test systems for hepatic metabolism. Predictive toxicogenomics and proteomics markers will be identified. The individual tests will be integrated into an ""all-in-one"" test system. To enable future industrial use ESNATS will prepare automating and scaling up of hESC culture. The predictivity, quality and reproducibility of ESNATS will be evaluated in a proof of concept study. ESNATS benefits are to increase safety due to better predictivity of human test systems, to reduce, refine and replace animal tests, to lower testing cost, and to support medium/high throughput testing. ESNATS objectives will be achieved in a 5 year multi-disciplinary collaboration of leading European researchers in alternative testing, toxicology, ESC research, genomics, modelling, and automation. The consortium will also include representatives from regulatory bodies, the pharmaceutical industry and ethical advisors to provide guidance to ensure rapid applicability of the developed tests systems."

Dziedzina nauki

Słowa kluczowe

Program(-y)

Temat(-y)

Zaproszenie do składania wniosków

FP7-HEALTH-2007-A
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

CP-IP - Large-scale integrating project

Koordynator

KLINIKUM DER UNIVERSITAET ZU KOELN
Wkład UE
€ 2 825 955,59
Adres
Kerpener Strasse 62
50937 Koeln
Niemcy

Zobacz na mapie
Region
Nordrhein-Westfalen Köln Köln, Kreisfreie Stadt
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Jutta Landvogt (Ms.)
Linki
Koszt całkowity
Brak danych

Uczestnicy (32)

Udostępnij tę stronę

Pobierz

Ostatnia aktualizacja: 16 Lipca 2019

Moja broszura

Permalink: https://cordis.europa.eu/project/id/201619/pl

European Union, 2024